Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 Infection

PURPOSE: Neutralizing antibodies can reduce SARS-CoV-2 cellular entry, viral titers, and pathologic damage. CT-P59 (regdanvimab), a SARS-CoV-2 neutralizing monoclonal antibody, was examined in 2 randomized, double-blind, placebo-controlled, single ascending dose, Phase I studies. METHODS: In study 1...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Jin Yong, Jang, Young Rock, Hong, Jang Hee, Jung, Jin Gyu, Park, Jae-Hyeong, Streinu-Cercel, Adrian, Streinu-Cercel, Anca, Săndulescu, Oana, Lee, Sang Joon, Kim, Sung Hyun, Jung, Na Hyun, Lee, Seul Gi, Park, Jeong Eun, Kim, Min Kyung, Jeon, Da Bee, Lee, Yeo Jin, Kim, Bum Soo, Lee, Yeon Mi, Kim, Yeon-Sook
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Inc. 2021
Materias:
COVID Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380488/
https://www.ncbi.nlm.nih.gov/pubmed/34551869
http://dx.doi.org/10.1016/j.clinthera.2021.08.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8380488/
https://www.ncbi.nlm.nih.gov/pubmed/34551869
http://dx.doi.org/10.1016/j.clinthera.2021.08.009

Ejemplares similares